Paradigm Biocapital Advisors’s Cidara Therapeutics CDTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-759,565	Closed	-$168M	–	37
2025 Q4	$168M	Sell	759,565 -201,599	-21%	-$32.6M	4.28%	10
2025 Q3	$92M	Buy	+961,164	New	+$61.3M	2.62%	13

Paradigm Biocapital Advisors's CDTX Position: Q1 2026 in Review

Paradigm Biocapital Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 759,565 shares — an estimated $168M sold.

Paradigm Biocapital Advisors first reported a position in CDTX in Q3 2025 and held it in 2 quarters. The position peaked at $168M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Paradigm Biocapital Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Paradigm Biocapital Advisors sold 759,565 Cidara Therapeutics shares in Q1 2026, an estimated $168M.
Paradigm Biocapital Advisors first reported a position in Cidara Therapeutics in Q3 2025 and held it in 2 quarters.
Paradigm Biocapital Advisors's Cidara Therapeutics position peaked at $168M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.